Additional file 1: Figure S1. Plot of log (−log (progression-free survival ratio)) versus log (days of progression-free survival). Hazard proportionality was tested by the parallelism between the curve of rs671(−) (cases with ALDH2*1/*1) and rs671(+) (cases with ALDH22*1/*2 and ALDH2*2/*2) to examine the suitability for the Cox proportional hazard model. Table S1. Immune-related adverse events (IrAEs) and second or subsequent ICI doses. Sas code. SAS code for the Cox proportional hazards model using time-dependent explanatory variables. Table S2. Overall best response per RECIST Ver1.1. by ALDH2 genotype limited to patients with non-small cell lung cancer. Table S3. Progression-free survival rate after the initiation of immune checkpoint inhibitors limited to patients with non-small cell lung cancer. Table S4. Hazaed ratio of cancer progression estimated from a 6-month observation in the model 4 in Table 4. Figure S2. Overall survival after the initiation of immune checkpoint inhibitor therapy. Kaplan–Meier plots were shown for patients with chest malignancies. ICI, immune checkpoint inhibitor; Rs671(−), ALDH2*1/*1 (n = 56), rs671(+); ALDH2*1/*2 or ALDH2*2/*2 (n = 49). p, p value for Gahan–Breslow–Wilcoxon test. Table S5. Hazard ratio of overall death for ALDH2*2 carriers estimated from a 6-month observation. Table S6. Stratified hazard ratio of overall death for ALDH2*2 carriers estimated from a 6-month observation.
